Brokerages Set ANI Pharmaceuticals Inc (NASDAQ:ANIP) Price Target at $84.25

Share on StockTwits

Shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) have been given a consensus rating of “Buy” by the eight ratings firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $84.25.

ANIP has been the topic of a number of recent analyst reports. BidaskClub raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 12th. ValuEngine cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Guggenheim initiated coverage on shares of ANI Pharmaceuticals in a research note on Thursday, September 12th. They set a “buy” rating and a $76.00 price target on the stock.

In related news, major shareholder Meridian Venture Partners Ii L sold 7,579 shares of the stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $68.21, for a total value of $516,963.59. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last three months, insiders sold 98,451 shares of company stock worth $7,006,801. 24.70% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. New York State Common Retirement Fund grew its stake in ANI Pharmaceuticals by 3.4% in the 1st quarter. New York State Common Retirement Fund now owns 23,494 shares of the specialty pharmaceutical company’s stock valued at $1,657,000 after acquiring an additional 780 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth about $211,000. THB Asset Management boosted its stake in shares of ANI Pharmaceuticals by 251.2% during the 2nd quarter. THB Asset Management now owns 89,305 shares of the specialty pharmaceutical company’s stock worth $7,340,000 after purchasing an additional 63,874 shares during the last quarter. Wedge Capital Management L L P NC boosted its stake in shares of ANI Pharmaceuticals by 8.6% during the 2nd quarter. Wedge Capital Management L L P NC now owns 7,386 shares of the specialty pharmaceutical company’s stock worth $607,000 after purchasing an additional 586 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth about $797,000. 70.77% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:ANIP opened at $72.69 on Tuesday. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 0.32. ANI Pharmaceuticals has a fifty-two week low of $36.92 and a fifty-two week high of $86.96. The stock has a market cap of $894.26 million, a PE ratio of 15.77 and a beta of 2.22. The firm’s fifty day simple moving average is $70.72 and its 200-day simple moving average is $71.91.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.18 by $0.26. ANI Pharmaceuticals had a net margin of 8.14% and a return on equity of 29.53%. The business had revenue of $54.36 million for the quarter, compared to analysts’ expectations of $55.20 million. During the same period in the prior year, the company posted $1.13 EPS. The business’s revenue for the quarter was up 15.0% on a year-over-year basis. Equities analysts anticipate that ANI Pharmaceuticals will post 5.29 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Further Reading: What causes a yield curve to invert?

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.